Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol

• Status: Recruiting
• Trial end date: 2021-12-14
• Target enrollment: 0
• Participant gender: All

Summary

To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hui-Sheng Chen
• Treatments: Edaravone

Criteria

Inclusion Criteria:

1. 18 to 80 years of age;

2. Patients who presented with acute ischemic stroke and a large vessel occlusion in the anterior circulation and met the criteria of mechanical thrombectomy;

3. Sufficient recanalization within 9 hours of stroke onset;

4. Sufficient recanalization （TICI 2b-3）;

5. Acute ischemic stroke with neurological baseline deficit equivalent to the National Institute of Health Stroke Scale (NIHSS) ≥ 6 before recanalization treatment;

6. First ever stroke or mRS≤1 after previous disease

7. The availability of informed consent.

Exclusion Criteria:

1. Acute ischemic stroke patients with insufficient recanalization（TICI < 2a）

2. Hemorrhagic transformation (PH2) indicated by NCCT performed after the operation immediately;

3. Hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage;

4. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ <100000/mm3）;

5. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;

6. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);

7. Patients with malignant tumor or under antineoplastic therapy with estimated lifetime less than 3 months;

8. Pregnancy, plan to get pregnant or during lactation;

9. Patients with contraindication or allergic to any ingredient of drugs in our study;

10. Unsuitable for this clinical studies assessed by researcher.